Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.68 |
| ▸ | LTA4H | P09960 | 1/20 | 0.67 |
| ▸ | BACE1 | P56817 | 1/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567941 | 0.99 | HRH3 (0.70) | HRH3LTA4HBACE1HRH1KCNH2 | |
| SCHEMBL21462645 | 0.88 | HRH3 (0.86) | HRH3LTA4HBACE1HRH1KCNH2 | |
| SCHEMBL3133804 | 0.83 | HRH3 (0.70) | HRH3LTA4HBACE1HRH1KCNH2 | |
| SCHEMBL491712 | 0.82 | HRH3 (0.97) | HRH3LTA4HBACE1KCNH2KDM4E | |
| SCHEMBL14287622 | 0.82 | HRH3 (0.77) | HRH3KCNH2 | |
| SCHEMBL2568425 | 0.81 | HRH3 (0.64) | HRH3LTA4HBACE1HRH1KCNH2 | |
| SCHEMBL5858684 | 0.81 | HRH3 (0.95) | HRH3LTA4HBACE1KCNH2KDM4E | |
| SCHEMBL2573680 | 0.81 | HRH3 (0.66) | HRH3LTA4HBACE1HRH1KCNH2 | |
| SCHEMBL4283657 | 0.79 | KDM4E (0.74) | LTA4HBACE1KDM4E | |
| SCHEMBL4386868 | 0.78 | KDM4E (0.60) | HRH3KCNH2KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | HRH3 597/4885LTA4H 1776/4885BACE1 2870/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | HRH3 504/4885LTA4H 1619/4885BACE1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.